Polymeric Modification NP Preparation Method % EE* Status References PLGA ― emulsion-solvent evaporation 85 in-vitro [14] PLGA , PLGA-PEG, PCL-PEG nanoprecipitation 70 in-vivo [15] Poloxamer 188 interfacial deposition >90 in-vitro [16] TPGS [emulsifier] emulsion-solvent evaporation 100 in-vitro [24] DLPC [emulsifier] emulsion-solvent evaporation 15-56 in-vitro [28] DPPC [emulsifier] emulsion-solvent evaporation 34-45 in-vitro [29] chitosan emulsion-solvent evaporation 75-79 in-vitro [19] DMAB emulsion-solvent evaporation 47 in-vivo [21] MMT emulsion-solvent evaporation ~50 in-vitro [30] MMT HER2 [targeting] emulsion-solvent evaporation ~50 in-vitro [31] RGD [targeting] emulsion-solvent evaporation 60-65 in-vivo [32] pluronic P85 transferrin [targeting] nanoprecipitation 70-76 in-vivo [33] PCL PEO-PCL solvent displacement >95 in-vivo [63, 64] PCL-pluronic F68 emulsion-solvent evaporation 84 in-vivo [72] PCL-pluronic F68 DMAB modified solvent displacement 76-88 in-vivo [193] mPEG-PCL Angiopep [targeting] emulsion and evaporation 90 in-vivo [67, 68] mPEG-PCL solid dispersion 98 in-vivo [69] PVP-b-PCL modified nanoprecipitation 85 in-vivo [73] PEG-PCL co-solvent extraction ― in-vivo [66] PEG-PCL folic acid [targeting] dialysis ― in-vitro [70] PCL-g-PVA dialysis ― in-vitro [74] PEtOz-PCL dialysis 5-76 in-vitro [75] PCL-PEEP galactosamine [targeting] dialysis ― in-vitro [76] PLA PLA-PEG [diblock] thin film 65 in-vivo [49] PLA-PEO [star-branch] solvent evaporation 6-56 in-vitro [48] PVA-PEG solvent evaporation 20-62 in-vitro [50] Poly[γ-glutamic acid] galactosamine [targeting] solvent evaporation 50-54 in-vivo [51] PLA-PEG-PLA PEG-PLA-PEG solvent evaporation 14-31 in-vivo [52, 53] Chitosan cholanic acid dialysis 92 in-vivo [78, 194] oligomer dialysis 97 in-vivo [79] glyceryl monooleate emulsion-solvent evaporation 98-100 in-vitro [80] mPEG, cholesterol dialysis 70 in-vivo [81] N-acetyl histidine ― ― in-vitro [82] stearic acid, glutaraldehyde ultrasonication 94-99 in-vitro [83] Gelatin ― desolvation > 80 in-vivo [109-112] HA ― desolvation 90 in-vivo [95] oligomer dialysis ― in-vitro [96] PBCA pluronic F127 miniemulsion 80 in-vitro [98] chitosan dialysis 90 in-vivo [99] surfactants [dextran 70, cholesterol, PVA, and lecithin] Polymerization 60-80 in-vitro [100] Albumin ― high-pressure homogenization ― approved [88] CREKA and LyP-1 peptides [targeting] ― ― in-vivo [91] folic acid [targeting] desolvation 95 in-vitro [92] octaldehyde dialysis 90 in-vitro [93] HPG PEG, PEI solvent evaporation ― in-vivo [102] PEG-PE EPC, solid triglycerides, cationic Lipofectin lipids solvent evaporation ~100% in-vivo [103-106]

Table 1: Summary of PX-loaded Polymeric NPs. [*EE=Entrapment Efficiency].